Paresh N. Soni
Corporate Officer/Principal bei American Gastroenterological Association
Profil
Paresh N.
Soni is the founder of Soni Biopharma Consulting LLC, founded in 2018.
He is currently a Member at American Gastroenterological Association.
Previously, he held the position of Vice President-Global Medical Sciences at Alexion Pharmaceuticals, Inc. from 2014 to 2016, Senior Vice President, Head-Research & Development at Amarin Corp.
Plc in 2012-2013, and Chief Medical Officer at Albireo Pharma, Inc. from 2016 to 2018.
He was also a Chief Clinical & Regulatory Strategist at Cardax, Inc. and a Member at American Association for The Study of Liver Diseases.
Dr. Soni holds a doctorate degree from the University of London.
Aktive Positionen von Paresh N. Soni
Unternehmen | Position | Beginn |
---|---|---|
American Gastroenterological Association
American Gastroenterological Association Miscellaneous Commercial ServicesCommercial Services American Gastroenterological Association engages in the science and practice of gastroenterology. The private company is based in Bethesda, MD. | Corporate Officer/Principal | 08.04.2011 |
Ehemalige bekannte Positionen von Paresh N. Soni
Unternehmen | Position | Ende |
---|---|---|
ALBIREO PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 03.08.2018 |
ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.07.2016 |
Soni Biopharma Consulting LLC | Gründer | - |
CARDAX, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
American Association for The Study of Liver Diseases
American Association for The Study of Liver Diseases Miscellaneous Commercial ServicesCommercial Services American Association for The Study of Liver Diseases engages in advancing and disseminating he science and practice of hepatology to preventing and cure liver disease. The company was founded by Hans Popper, Leon Schiff, Fred Hoffbauer, Cecil Watson, Jesse Bollman, and Sheila Sherlock in 1950 and is headquartered in Alexandria, VA. | Corporate Officer/Principal | - |
Ausbildung von Paresh N. Soni
University of London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
AMARIN CORPORATION PLC | Health Technology |
CARDAX, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
American Association for The Study of Liver Diseases
American Association for The Study of Liver Diseases Miscellaneous Commercial ServicesCommercial Services American Association for The Study of Liver Diseases engages in advancing and disseminating he science and practice of hepatology to preventing and cure liver disease. The company was founded by Hans Popper, Leon Schiff, Fred Hoffbauer, Cecil Watson, Jesse Bollman, and Sheila Sherlock in 1950 and is headquartered in Alexandria, VA. | Commercial Services |
American Gastroenterological Association
American Gastroenterological Association Miscellaneous Commercial ServicesCommercial Services American Gastroenterological Association engages in the science and practice of gastroenterology. The private company is based in Bethesda, MD. | Commercial Services |
Albireo Pharma, Inc.
Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
Soni Biopharma Consulting LLC |